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The p53 protein is encoded by the p53 tumour suppressor gene and
plays a crucial role in the protection of our cells against a geno-
toxic stress. This nuclear phosphoprotein is expressed at a very
low level and is hardly detectable in normal cells. Alteration of the
p53 tumour suppressor gene is the most frequent genetic event
found in human cancer and leads to loss of function and accumula-
tion of the inactive p53 protein in malignant cells (Hollstein et al,
1991). 
Human anti-p53 antibodies have been described as early as
1982 (Crawford et al, 1982). These anti-p53 antibodies are highly
specific of malignant diseases and their detection correlates with
inactivation of the p53 gene in tumoural cells (Collet et al, 1997;
Hammel et al, 1999). A number of studies have looked at their
usefulness as a marker of malignancy. These studies have shown
that anti-p53 antibodies were rarely detected in healthy donors and
patients with benign diseases and that in cancer patients their
prevalence varied from 2 to 25% according to the tumour studied
(Schlichtholz et al, 1992; Lubin et al, 1995; Hammel et al, 1997). 
Anti-p53 antibodies have appeared as complementary tumoural
markers in the follow-up of patients with colorectal or lung
cancers (Lubin et al, 1995; Zalcman et al, 1998). In these cancers,
anti-p53 antibodies, when positive, decrease rapidly in the 
context of therapeutic control of the disease and increase 
before the metastatic progression can be diagnosed by conventional
techniques. Furthermore, clinical studies have shown that anti-p53
antibodies are an independent prognostic factor of short survival in
breast cancer and head and neck epidermoid carcinoma (Peyrat
et al, 1995; Bourhis et al, 1996; Kaur et al, 1997). More impor-
tantly, anti-p53 antibodies have proven to be predictive markers
for the detection of a malignant tumour in high-risk patients such
as in chronic bronchitis patients for the early detection of lung
carcinoma (Lubin et al, 1995) or in dysplastic lesions of the oral
cavity for the further development of a carcinoma at the same loca-
tion (Kaur et al, 1997). All these results strongly support the
hypothesis that anti-p53 antibodies are a new tumoural marker of
great potential interest in clinical oncology. 
Because of the high frequency of p53 mutations in human skin
carcinomas (Basset-Séguin et al, 1994) and their occurrence as
early as in chronically sun-exposed skin (Ren et al, 1996), we
hypothesized that these tumours could be a perfect target for anti-
p53 antibody production. Most skin carcinomas can be detected by
inspection and biopsy. However, in patients with aggressive
tumours, clinical and radiological follow up after surgical treat-
ment or chemotherapy is often difficult because of local tissue
remodelling. Additionally, tumours on highly damaged skin in
patients having multiple and recurrent lesions are not easy to dia-
gnose. To our knowledge no data are available in the litterature on
the prevalence of anti-p53 antibodies and their usefulness as a
tumoral marker in skin carcinoma. To determine whether anti-p53
antibodies could be a relevant tumoural marker for skin carci-
noma, we conducted a prospective study to determine whether
anti-p53 antibodies were more frequent in skin carcinomas, in
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noma (SCC), than in skin-carcinoma-free patients. Additionally, in
order to confirm p53 gene alteration, which usually correlates with
detection of anti-p53 antibodies, we checked for p53 protein stabi-
lization in a sample of these tumours by immunohistochemistry. 
PATIENTS AND METHODS 
Patients 
Consecutive patients consulting at the Hôpital Saint-Louis for skin
carcinoma were prospectively enrolled in the study with the
following inclusion criteria: age > 18 years, histologically proven
skin carcinoma (BCC, SCC, adnexal tumours, Bowen, actinic
keratosis (AK)), no surgery, chemotherapy and/or radiotherapy yet
started, patient’s consent for a single blood sampling. For each
patient the following data were recorded independently of the
serological status to p53: age, gender, histological subtype,
number of tumours, existence of a genodermatosis predisposing to
cancer. Controls were chosen from patients coming in the derma-
tology day-care unit during the same study period. Their skin
carcinoma-free status was verified by patient’s history and
complete physical examination. These controls were matched with
the cases according to gender and age. 
From September 1997 to January 1999, 105 patients were
enrolled in the study. Main patients’ characteristics were age:
median 70 years (range 26–98 years), male gender 49.5% (n = 52).
The type and number of tumours are listed in Table 1. In the control
group (n = 130) the main characteristics were: age – median 63
years (range 25–97), male gender 48% (n = 63). The diagnoses of
the control group are shown in Table 2. 
Detection of p53 autoantibodies 
Detection of anti-p53 antibodies in human sera was made by using
a commercially available enzyme-linked immunoabsorbent assay
kit (anti-p53 ELISA, Pharmacell, France). Sera were diluted to
1/100 and incubated for 1 hour in the microplates. After washing,
goat anti-human IgG antibody conjugated with peroxidase was
added for 1 hour. Next, the substrate 3, 3′ , 5, 5′ tetramethylbenzi-
dine (TMB) was added for 10 min and the enzymatic process was
halted by adding 2N sulfuric acid. Light absorption was measured
at 450 nm using a phosphospectrometer. Because human sera may
give rise to variable background signals, each sample was tested
simultaneously in 2 distinct wells. One well was coated with
recombinant wild-type human p53 protein to detect specific anti-
p53 antibodies. The other well was coated with control proteins to
detect non-specific interactions. The presence of anti-p53 anti-
bodies in the sample was determined according to the manufac-
turer for 2 parameters at threshold levels, allowing evaluation of
the sample compared with controls. 
Immunohistochemistry 
Skin samples fixed in 10% formalin, were deparaffinized, and
stained after antigen retrieval in a microwave oven 15 m, at 450 w
in tris buffer pH 7.3 with monoclonal antibody D-07 (Dako, code
M7001), which reacts with both wild-type and mutant forms of
the human p53 protein, at a dilution of 1:50, and revealed by
avidin–biotin-coupled immunoperoxidase staining method and
diaminobenzidin. A positive control (a p53 mutated tumour) was
always added. Staining was nuclear and was negative when
omiting the primary antibody. A tumour was found positive if at
least 30% of nuclei were stained. Staining intensity was graded +
if nuclei were light brown, ++ if nuclei were brown and +++ if
nuclei were dark brown. Mayer’s haematoxylin was used for
counterstaining. Slides were read by 2 pathologists independently. 
Statistical analysis 
Comparisons between groups were performed with Fisher’s exact
test for categorical variables; 95% confidence intervals (95% CI)
of percentages were calculated with the exact binomial method. 
2-sided tests were computed, and P values of 0.05 or less were
considered statistically significant. The SAS software (SAS
Institute, Cary, NC) was used. 
RESULTS 
Prevalence of anti-p53 antibodies 
The estimated prevalence of anti-p53 antibodies among patients
with skin carcinomas is shown in Table 3. 
In the control group, the estimated prevalence of anti-p53 anti-
bodies was 2/130 (0.015, 95% CI: 0–0.05). 
There was no significant difference of anti-p53 antibodies preva-
lence between skin cancer patients and controls (P = 0.66); BCC
patients and controls (P = 1.00); SCC patients (8%) and controls
(1.5%) (P = 0.12); SCC patients and BCC patients (P = 0.17). 
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Table 1 Skin tumour type in our series of patients 
Tumour type Unique Multiple 
BCC 39 29 
SCC 22 3 
BCC + SCC – 2 
Bowen 3 –
Sweat gland carcinoma 1 –
Actinic keratosis – 2 
NK 4 –
Total 69 36 
BCC: patients with basal cell carcinoma alone; SCC: patients with squamous
cell carcinoma alone; BCC + SSC: patients with both SCC and BCC; NK:
skin carcinoma type not known. 
Table 2 Diagnoses of the control group 
Dermatoses Number of patients analysed 
Allergic dermatitis 14 
Auto-immune diseases 20 
Prurigo 19 
Cutaneous lymphoma 21 
Psoriasis, neutrophilic 6 
dermatosis 
Lichen 2 
Vasculitis 2 
Sarcoidosis 6 
Benign lymphocytic infiltrate 13 
Other 20 
Not determined 7 
Total 130 Positive sera levels were: 1.31, 4.4 and 5.23 with a threshold of
positivity of 1.1. 
p53 stabilization in the skin tumour 
Among the 105 patients tested for anti-p53 antibody, a sample
of 35 tumours (26/39 BCC and 8/25 SCC and 1 Bowen) was
randomly selected and analysed for p53 stabilization by immuno-
histochemistry in order to check for evidence of p53 protein accu-
mulation. Among the tumours analysed 80% (n = 28/35) showed
positive nuclear staining within the tumoural nest. All were graded
as ++ or +++. Histological types of p53-positive tumours are
shown in Table 3. Among the 3 patients with circulating anti-p53
antibodies, one had a p53-positive tumour, one had a negative
tumour and the third one could not be analysed. 
DISCUSSION 
We estimated in this controlled prospective study the prevalence
of circulating anti-p53 antibodies in skin carcinoma patients.
Surprinsingly the high rate of p53 mutation reported by us and
others for these tumours contrasted with the low prevalence of
anti-p53 antibodies. This paradox is a rare phenomenon showing
the complexity of the anti-p53 humoral response. Clearly, anti-p53
antibodies can not serve as early indicators for skin cancer-prone
high-risk patients. However, anti-p53 antibody prevalence was
higher in the most aggressive forms of SCC which suggest then
when positive, these antibodies could serve to follow rare difficult
non-surgical SCC cases during the course of therapy. 
Circulating anti-p53 antibodies have been shown to be useful as
prognostic and predictive tumoural markers in a number of human
neoplasms, in which the p53 protein is accumulated. The preval-
ence of anti-p53 antibodies varies according to the tumour group
analysed: 24–25% in colon or lung cancer, 12–19% in breast,
bladder and pancreas cancer, and 3–4% in leukaemia or thyroid
carcinomas. The prevalence of anti-p53 antibodies varies also with
the detection method used, as immunofluorometry detection yields
lower prevalences than the ELISA technique in all the studied
tumours but with the same proportional differences. 
In our series of patients the prevalence of anti-p53 antibodies
was low (2.9%). This can not be due to a technical artefact as
the ELISA assay that we used is the one commonly performed
in many previously published studies. This low prevalence
contrasted with the high rate of p53 mutations classically reported
for these tumours (Basset-Séguin et al, 1994). A recent review of
over 130 papers published in the field since 1992 showed a strong
correlation between anti-p53 antibody detection and the presence
of p53 mutation in the tumour in most human cancers (Soussi,
2000). One exception to this is the observation of a poor anti-p53
humoral response in gliomas in which p53 mutation rate is high
(Rainov et al, 1995). Hypothetical explanation for this paradox is the
immune privilege of the brain not allowing this humoral response or
an inefficient antigen presentation due to the brain barrier or even a
locally non-effective immune response. Additionally dexamethasone
intake reported for 70% of the glioma patients before serum collec-
tion could have impaired the patient’s immune capacity. 
To check if the low prevalence of anti-p53 antibodies in our skin
carcinoma patients was not due to a low prevalence of p53 gene
alteration, we looked for p53 protein accumulation by immuno-
histochemistry in a randomly selected subgroup of 35 patients.
Elevated levels of p53 protein were detected in 80% of the
tumours analysed which confirmed the frequent alteration of this
pathway classically reported in skin carcinomas. One patient with
circulating anti-p53 antibodies was found to have an accumulation
of the P53 protein in its tumour. Another one was found negative
but that does not mean that its tumour was not p53-mutated as
mutation leading to protein conformational changes or stop muta-
tion can be associated with lack of p53 protein accumulation. The
third patient could not be evaluated for immunohistochemistry. 
The differences in anti-p53 antibody prevalences among
patients with p53-mutated tumours could be influenced by several
factors. 
1. p53 mutation location: although initially suggested, it is
unlikely as a recent a compilation of serological analyses
performed in association with molecular analysis has shown
that p53 mutation do not differ between patients with or
without anti-p53 antibodies (Soussi, 2000). 
2. Tumour location: interestingly more than 80% of skin carci-
nomas are localized in sun-exposed skin and it is well known
that sun-exposure has local as well as systemic immunosup-
pressive properties by affecting cytokine production and the
number and capacity of antigen-presenting cells (Beissert and
Schwarz, 1999). Thus we could hypothesize that sun-exposed
human skin fails to elicit an efficient anti-p53 humoral
response. Our patients were not immunocompromised but
most of their tumour located in highly sun exposed skin.
Indeed in our series, only one patient with circulating anti-p53
antibodies had a lesion on highly sun-exposed skin (forehead)
and the 2 others had a tumour on moderately sun-exposed skin
(back) or non-sun-exposed skin (vulva). In another UV-related
tumour, melanoma, in which the p53 protein is frequently
found accumulated but without concomitant mutation of the
gene, a very small percentage (2%) of anti-p53 antibodies have
also been detected (Angelopoulou, 1994). 
3. Tumour thickness and tumoural mass could also be responsible
for the poor immunization against p53 as skin tumours are
often of small size. However, 3 of our patients suffered from
Gorlin’s syndrome, a genodermatosis predisposing to the
development of numerous BCC, and beared between 30 and
> 100 tumours which represent a large overall tumoural mass
and had no anti-p53 antibodies. 
To determine whether anti-p53 antibody prevalence differed between
skin carcinoma and skin carcinoma-free patients recruited in a
dermatology department, we estimated the anti-p53 antibodies preva-
lence in a control group including mostly chronic inflammatory
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Table 3 Prevalence of circulating anti-p53 antibodies and tumoural p53
immunoreactivity in our series of patients 
Tumour type Anti-p53 antibodies Tumour p53 + (IHC) 
BCC 1.5% (1/68) 95% CI: (0–0.08) 85% (22/26) 
SCC 8% (2/25) 95% CI: (0.01–0.26) 62% (5/8) 
BCC + SCC 0% (0/2) ND 
Bowen 0% (0/3) 100% (1/1) 
Adnexal carc 0% (0/1) ND 
AK 0% (0/2) ND 
NK 0% (0/4) ND 
Total tumours 2.9% (3/105) 80% (28/35) 
NK: not known; Adnexal carc: adnexal carcinoma; AK: actinic keratosis; ND:
not determined; IHC: immunohistochemistry. 95% confidence intervals (95%
CI) are given for BCC and SCC alone. dermatoses. Circulating anti-p53 antibodies were found in 
2 out of 130 patients (1.5%). In the literature, the prevalence of
anti-p53 antibodies in healthy donors has been shown to be 0.5%
and in non-tumoural human pathology 1% (Schlichtholz et al,
1992; Lubin et al, 1995; Hammel et al, 1997). It is noteworthy that
most studies on p53 antibodies in human tumours have not been
performed with a tumour-free control group. Additionally, it has
been shown that in non-tumoural inflammatory diseases such
as rhumatoid arthritis, p53 accumulation could be found in the
synovium (Firestein et al, 1996). The 2 skin carcinoma-free
patients found to have anti-p53 antibodies were diagnosed as
rheumatoid purpura and chronic urticaria. 
In conclusion this is the first study reporting the prevalence
of anti-p53 antibodies in skin carcinoma. Surprisingly, these
frequently p53-mutated skin tumours are associated with a low
prevalence of anti-p53 antibodies. UV-induced immunosuppres-
sion could explain in part this low prevalence. The highest preval-
ence of anti-p53 antibodies was observed in SCC patients
compared to BCC patients or controls. These results suggest that
these antibodies can not be used routinely in skin carcinoma
patients, however, in difficult SCC cases, they may be helpful to
follow response to therapy. 
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